Jennifer Dovey

Company: Triveni Bio

Job title: Chief Scientific Officer

Seminars:

Leveraging Genetically Guided Antibody Strategies to Repair Barrier Dysfunction and Immune Dysregulation in Atopic Dermatitis 4:00 pm

Dual inhibition of kallikrein‑5 and ‑7 offers a protease‑based mechanism that intersects barrier dysfunction, inflammation, and itch in AD Unlike standard Th2‑targeted biologics, targeting KLK5/7 represents an orthogonal pathway informed by Netherton syndrome genetics and human expression datasets ex vivo human explant data show rapid improvements in epidermal integrity, reduced keratinocyte proliferation, and restoration of…Read more

day: Day One PM